Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer by unknown
Yip-Schneider et al. BMC Cancer 2013, 13:194
http://www.biomedcentral.com/1471-2407/13/194RESEARCH ARTICLE Open AccessDimethylaminoparthenolide and gemcitabine: a
survival study using a genetically engineered
mouse model of pancreatic cancer
Michele T Yip-Schneider1*, Huangbing Wu1, Keith Stantz2, Narasimhan Agaram3, Peter A Crooks8
and C Max Schmidt1,4,5,6,7*Abstract
Background: Pancreatic cancer remains one of the deadliest cancers due to lack of early detection and absence of
effective treatments. Gemcitabine, the current standard-of-care chemotherapy for pancreatic cancer, has limited
clinical benefit. Treatment of pancreatic cancer cells with gemcitabine has been shown to induce the activity of the
transcription factor nuclear factor-kappaB (NF-κB) which regulates the expression of genes involved in the
inflammatory response and tumorigenesis. It has therefore been proposed that gemcitabine-induced NF-κB
activation may result in chemoresistance. We hypothesize that NF-κB suppression by the novel inhibitor
dimethylaminoparthenolide (DMAPT) may enhance the effect of gemcitabine in pancreatic cancer.
Methods: The efficacy of DMAPT and gemcitabine was evaluated in a chemoprevention trial using the mutant Kras
and p53-expressing LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mouse model of pancreatic cancer. Mice were
randomized to treatment groups (placebo, DMAPT [40 mg/kg/day], gemcitabine [50 mg/kg twice weekly], and the
combination DMAPT/gemcitabine). Treatment was continued until mice showed signs of ill health at which time
they were sacrificed. Plasma cytokine levels were determined using a Bio-Plex immunoassay. Statistical tests used
included log-rank test, ANOVA with Dunnett’s post-test, Student’s t-test, and Fisher exact test.
Results: Gemcitabine or the combination DMAPT/gemcitabine significantly increased median survival and
decreased the incidence and multiplicity of pancreatic adenocarcinomas. The DMAPT/gemcitabine combination
also significantly decreased tumor size and the incidence of metastasis to the liver. No significant differences in the
percentages of normal pancreatic ducts or premalignant pancreatic lesions were observed between the treatment
groups. Pancreata in which no tumors formed were analyzed to determine the extent of pre-neoplasia; mostly
normal ducts or low grade pancreatic lesions were observed, suggesting prevention of higher grade lesions in
these animals. While gemcitabine treatment increased the levels of the inflammatory cytokines interleukin 1α (IL-1α),
IL-1β, and IL-17 in mouse plasma, DMAPT and DMAPT/gemcitabine reduced the levels of the inflammatory cytokines
IL-12p40, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 beta (MIP-1β), eotaxin, and
tumor necrosis factor-alpha (TNF-α), all of which are NF-κB target genes.
Conclusion: In summary, these findings provide preclinical evidence supporting further evaluation of agents such as
DMAPT and gemcitabine for the prevention and treatment of pancreatic cancer.
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Pancreatic adenocarcinoma is the fourth leading cause of
cancer-related deaths in the United States, with mortality
nearly equal to incidence. Less than 5% of patients survive
five years from the time of diagnosis, and the median sur-
vival time is less than 6 months. This year alone, pancreatic
cancer will result in approximately 40,000 deaths in the
United States [1]. At the time of diagnosis, surgical resection
is unfortunately not an option for many patients due to the
advanced stage of disease and distant metastases. In addition,
current chemotherapeutic strategies are largely ineffective
because of either innate or acquired chemoresistance.
Gemcitabine (2’,2’-difluorodeoxycytidine) is the drug of
choice for the primary treatment of unresectable pancreatic
cancer and adjuvant treatment following resection of pancre-
atic cancer, but measurable responses are not observed in
the majority of patients [2,3]. Fortunately, gemcitabine, com-
pared to other chemotherapeutic agents, is relatively non-
toxic [4]; however, its use as chemoprevention in patients
with known precancerous lesions has not been explored.
Other chemotherapeutic agents, e.g., paclitaxel, have recently
been used in patients with precancerous pancreatic lesions
with some evidence of regression [5].
To aid in the search for effective prevention and interven-
tion strategies, clinically relevant animal models are needed
and have recently been developed [6]. For example, a genet-
ically engineered mouse model of pancreatic cancer with
targeted expression of mutant KRASG12D and Trp53R172H
genes has been shown to recapitulate human pancreatic
neoplasia, from premalignant lesions to invasive cancer and
metastasis [7]. The LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-
Cre mice are a developmental model of pancreatic cancer
in which adenocarcinoma form de novo with close to 100%
penetrance. In this mouse model, the Lox-Stop-Lox (LSL)
sequence upstream of oncogenic KRAS and mutant Trp53
inhibits transcription and translation. Expression of Cre
recombinase from the pancreatic-specific promoter Pdx-1,
excision of the “Stop” sequences, and subsequent Cre-
mediated recombination allow endogenous expression of
the mutant Kras and p53 in progenitor cells of the mouse
pancreas. Another advantage of this model is that the nat-
ural microenvironment of the pancreas is maintained.
Thus, preclinical data from these types of animal models
may be more predictive of human clinical outcomes.
Due to its critical role in inflammation and multiple
tumorigenic processes, the transcription factor nuclear
factor-kappaB (NF-κB) is a therapeutic target of interest
for pancreatic cancer [8,9]. In addition, the p65 subunit of
NF-κB, RelA, is constitutively active in human pancreatic
adenocarcinoma tissue and in pancreatic tumor cell lines
[10]. It was recently demonstrated in a genetically
engineered mouse model that constitutive NF-κB activa-
tion, by Kras through AP-1-induced overexpression of
interleukin-1α (IL-1α), is required for the development ofpancreatic cancer [11]. These findings implicate NF-κB in
the development and progression of pancreatic cancer.
Furthermore, experimental evidence suggests that NF-κB
may also be a suitable target for chemoprevention [12,13].
We have previously examined the anti-cancer activity of
dimethylaminoparthenolide (DMAPT), which is a novel
and orally bioavailable analog of parthenolide, a sesquiter-
pene lactone isolated from the medicinal herb feverfew
(Tanacetum parthenium) [14]. In both xenograft and
carcinogen-induced animal models of pancreatic cancer,
DMAPT inhibits the activity of NF-κB and shows thera-
peutic promise in combination with the anti-inflammatory
agents sulindac or celecoxib in vivo [15,16].
We and others have also reported that the chemother-
apeutic agent gemcitabine induces NF-κB activity in
pancreatic cancer cells in vitro, suggesting that NF-κB
activation may play a role in chemoresistance to
gemcitabine [9,17-20]. A viable strategy for improving
the therapeutic response to gemcitabine may therefore
involve suppression of the NF-κB pathway. In support,
we recently demonstrated that DMAPT not only inhibits
gemcitabine-induced NF-κB activation but also sensi-
tizes pancreatic cancer cells to the anti-proliferative ef-
fects of gemcitabine in vitro, indicating that the level of
NF-κB activity modulates the gemcitabine response [21].
Furthermore, in a heterotopic xenograft model, gemcitabine
exposure activates NF-κB within established pancreatic
tumors, suggesting that NF-κB suppression may also im-
prove the anti-tumor effects of gemcitabine in vivo [21].
Most recently, we found that DMAPT and/or sulindac in
combination with gemcitabine therapy can delay or prevent
progression of premalignant pancreatic lesions in the less
aggressive LSL-KrasG12D/+; Pdx-1-Cre mouse model of pan-
creatic cancer [22]. Due to the low incidence of pancreatic
tumors in the LSL-KrasG12D/+; Pdx-1-Cre mouse model, the
clinical relevance of this delay on pancreatic tumor forma-
tion or metastasis could not be determined. Thus, the
chemopreventative efficacy of the most effective combin-
ation DMAPT/gemcitabine was further evaluated in this
survival study using the LSL-KrasG12D/+; LSL-Trp53R172H;
Pdx-1-Cre mouse model, which is characterized by near
100% incidence of pancreatic adenocarcinoma development.
Methods
Compounds
Gemcitabine (GEMZAR®) was obtained from Eli Lilly
(Indianapolis, IN). DMAPT [14] was synthesized by re-
action of parthenolide (Sigma-Aldrich, St. Louis, MO)
with dimethylamine (Sigma-Aldrich, St. Louis, MO) and
isolated as the fumarate salt.
LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mouse model
This study was performed in compliance with federal Institu-
tional Animal Care and Use Committee guidelines. Male
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Dr. Andrew Lowy, University of California, San Diego [23])
were crossed with female p53 LSL R172H (NCI-Frederick)
mice to generate LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre
mice. At 1 month of age, mice were genotyped by PCR
analysis of tail genomic DNA. For KrasG12D, primers were
as follows resulting in amplification products of 500 bp
(wild-type) and 550 bp (mutant allele):
50 wild type: GTCGACAAGCTCATGCGGG;
50 mutant (LSL element):
CCATGGCTTGAGTAAGTCTGC
30 universal: CGCAGACTGTAGAGCAGCG
For Cre, the primers were as follows to generate a
475 bp amplification product:
50: AGATGTTCGCGATTATCTTC
30: AGCTACACCAGAGACGG
For p53R172H, primers were as follows generating amp-
lification products of 166 bp (wild-type) and 270 bp
(LSL element):




This breeding scheme resulted in ~12% positive mice
which were eligible for rolling enrollment in the study.
At 1 month of age, LSL-KrasG12D/+; LSL-Trp53R172H;
Pdx-1-Cre mice were randomized into treatment groups
(placebo, DMAPT, gemcitabine, DMAPT/gemcitabine).
Placebo (vehicle = hydroxylpropyl methylcellulose, 0.2%
Tween 80 [HPMT]) and DMAPT (40 mg/kg body
weight in HPMT) were administered by oral gastric lav-
age once daily. Gemcitabine (50 mg/kg body weight in
PBS) was administered by intraperitoneal injection twice
weekly. Mouse weight was monitored weekly. Treatment
was continued until mice showed signs of lethargy,
abdominal distension or weight loss at which time they
were sacrificed. Successful excision-recombination events
were confirmed in the pancreata of mice by detecting the
presence of a single LoxP site [24].
Upon necropsy, the presence and size of gross pancre-
atic tumors and metastases were noted. The presence of
multiple tumors was determined both by gross examin-
ation and palpation of the pancreas since the boundaries
between multiple large tumors can be difficult to delin-
eate in hematoxylin and eosin (H&E)-stained specimens.
In these cases, gross tumor dimensions were used for ana-
lysis. For the smaller tumors, identification of pancreatic
ductal adenocarcinoma, as well as their dimensions, wasconfirmed upon review of ten consecutive H&E-stained
sections per pancreas (100 μm apart) by a pathologist
blinded to the experimental groups. Tumor volume was
calculated using a modified ellipsoidal formula, 1/2
(length × width2). Liver, kidney, and lung were also exam-
ined for signs of drug toxicity. Pancreatic, liver and lung
tissue pieces (3 mm) were frozen in liquid nitrogen and
stored at −80°C for analysis; the remaining tissues were
fixed in 10% formalin (Sigma, St. Louis, MO) and
paraffin-embedded for H&E staining and immunohisto-
chemistry. Serial liver and lung sections (10–15 sections
each, 100 μm apart) were examined for metastases. Blood
(~ 1 ml) was obtained by cardiac puncture, mixed with
25 μl anticoagulant (EDTA [2 g]/NaCl [0.8 g] in 100 ml
water, pH 7.4) and centrifuged (2800 rpm, 15 minutes, 4°C).
Plasma aliquots were frozen at −80°C.
Luciferase-expressing p53f/f; LSL-KrasG12D;lucl/l; Pdx-1-Cre
mouse model
Floxed-p53/LSL-KrasG12D/floxed-STOP-luciferase male mice
(designated p53f/f; LSL-KrasG12D;lucl/l, breeders kindly pro-
vided by Dr. Robert Bigsby, Indiana University [25]) were
crossed with Pdx-1-Cre mice to generate p53f/f; LSL-
KrasG12D;lucl/l; Pdx-1-Cre mice, in which p53 is deleted
and mutant Kras and luciferase are expressed. After geno-
typing, mice were randomized into single agent treatment
groups (placebo, DMAPTand gemcitabine) at two months
of age as described above. Following injection with
D-luciferin (60 mg/kg, in 0.3 mL PBS) into the intra-
peritoneal cavity, imaging was performed using the
NightOWL optical Imager (LB981, Berthold) to de-
tect luciferase expression within the pancreas.
Mouse PanIN (mPanIN) analysis
One section per pancreas, with maximal exposure (greater
than 75%) of the pancreas (5 μm) was cut, stained with
hematoxylin and eosin (H&E), and examined microscopic-
ally for lesions. Sections from all animals in each treatment
group were analyzed. mPanINs were counted in a blinded
manner according to previously established criteria [26,27].
The highest grade lesion in the individual pancreatic lobules
within the entire pancreas from each animal was identified
for quantification. The percent normal ducts, mPanIN-1,
mPanIN-2 and mPanIN-3 lesions was determined relative
to the total number of lesions counted per pancreas.
Immunohistochemistry and staining
Immunohistochemistry was performed with primary
antibodies NF-κB/p65 (1:400, Lab Vision Corporation,
Fremont, CA), phospho-ERK (1:500, Cell Signaling, Danvers,
MA), Ki67 (1:50, Dako North America, Carpinteria, CA) and
CD31 (1:20, Dianova, Hamburg, Germany). Briefly, slides
were deparaffinized and hydrated in running water. Slides
were placed in Antigen Retrieval Citrate Buffer pH 6.0 (Dako
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placing in 3% H2O2 for 10 min. All slides were placed in Pro-
tein Block (Dako North America) for 15 min, incubated with
appropriate primary and secondary antibodies, and then
counterstained. Percent NF-κB and Ki67 staining was quan-
tified by counting the number of positively staining tumor
cells in two fields with the highest density of staining per
pancreas and expressed relative to the total number of cells
within the field. Intratumoral CD31 staining was quantified
using ImageScope software and the positive pixel count
algorithm (Aperio Technologies, Vista, CA).
Masson’s Trichrome was performed using Sigma-Aldrich
Accustain Trichrome Stains (Masson, kit No. HT-15) and
quantified using ImageScope software.
Cytokine analysis
Mouse plasma obtained at the time of sacrifice was analyzed
using the Bio-Plex Pro™ mouse cytokine 23-plex immuno-
assay (Biorad, Hercules, CA) and the Bio-Plex 200 System,
as recommended by the manufacturer. Samples were diluted
1:4 with sample diluent supplied in the Bio-Plex kit prior toA


















*P < 0.05 vs. placebo
Figure 1 The effect of treatment on median survival and tumor volume
each treatment group is shown in the Kaplan-Meier survival curve (placebo = 2
* P < 0.05 for gemcitabine and DMAPT/gemcitabine vs. placebo by log-rank te
treatment group is shown in the scatter plot. Note the difference in scale. Gemanalysis. Analyte values that were out of range or with a low
bead count (< 50) were excluded from analysis.
Statistical Analysis
Median survival was determined by the Kaplan-Meier
method and analyzed by the log-rank test. Comparisons
between placebo and treatment groups were analyzed by
ANOVA with Dunnett’s post-test or Student’s t-test
(Prism 5.0 software, Graphpad, San Diego, CA). For inci-
dence, Fisher exact test was performed. P < 0.05 was con-
sidered significant (two-tail, 95% confidence interval).
Results
Treatment of LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice
To test the chemopreventative efficacy of DMAPT and/or
gemcitabine, LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre
mice were randomized into one of the following treatment
groups at 1 month of age: placebo (n = 14), DMAPT
(40 mg/kg/day, n = 15), gemcitabine (50 mg/kg/dose, n = 14),
or DMAPT/gemcitabine (n = 15). The dose of DMAPT



























in LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice. A) Median survival for
17.5 days; DMAPT = 233 days; Gem= 254.5 days; DMAPT/Gem= 255 days).
st. B) The tumor volume of individual pancreatic tumors within each
, gemcitabine. * P < 0.05 vs. placebo.
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pancreatic cancer [15,16,22]. DMAPT is currently being
evaluated in clinical trials; however doses of 50-100 mg/kg
have been employed in vivo in canine and mouse models to
inhibit NF-κB, without any evidence of toxicity [28]. The
gemcitabine dose of 50 mg/kg twice weekly is equivalent to a
human dose of 300 mg/m2 using a body surface area (BSA)
normalization method; this is relatively low compared to the
standard human dosing regimen of 1000 mg/m2 given once
per week for 7 weeks [29-31].A
B C
Figure 2 Luciferase-expressing p53f/f; LSL-KrasG12D;lucl/l; Pdx-1-Cre mic
mice were injected with D-luciferin (60 mg/kg; i.p.) and imaged to detect b
point, a sequence of 15 images (2 minutes exposure time/image) was acqu
relative change in photon fluence rate, e.g., counts/min in each voxel, usin
noise). The optical geometry was identical for all imaging sessions. B) Total
14 mice). * P < 0.05 by two-tailed paired t-test. C) Median survival for each
= 126 days; DMAPT = 143 days; Gem = 155 days). * P < 0.05 for gemcitabineGemcitabine or the combination DMAPT/gemcitabine
prolong survival
Treatment of the LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre
mice with either gemcitabine or the combination DMAPT/
gemcitabine significantly increased the median survival
time by more than 30 days compared to the placebo
group (254.5 [P = 0.015] or 255 days [P = 0.018] vs.
217.5 days, respectively) (Figure 1A). The median sur-
vival for the DMAPT-treated mice (233 days), although
longer, was not significantly different from the placeboe. A) At 10 and 13 weeks of age, p53f/f; LSL-KrasG12D;lucl/l; Pdx-1-Cre
ioluminescence as shown for three representative mice. At each time
ired. The image with the peak bioluminescence was used to assess
g a lower threshold of 150 counts/min/sec (> 10 times background
photon flux (counts/min/tumor x 106) at 10 and 13 weeks of age (n =
treatment group is shown in the Kaplan-Meier survival curve (placebo
vs. placebo by log-rank test.
Table 1 Pancreatic tumor incidence, multiplicity and metastasis
Treatment Incidence (%) Incidence, T ≥ 500 mm3 (%) Multiplicity Metastasis (%) Liver met (%) Lung met (%)
Placebo 14/14 (100%) 11/14 (78%) 27/14 = 1.9 7/14 (50%) 6/14 (43%) 3/14 (21%)
DMAPT 11/15 (73%) 8/11 (73%) 18/15 = 1.2 5/11 (45%) 2/11 (18%) 5/11 (45%)
Gemcitabine 6/14 (43%)* 2/6 (33%) 6/14 = 0.4* 3/6 (50%) 3/6 (50%) 1/6 (17%)
DMAPT/gemcitabine 9/15 (60%)* 1/9 (11%)* 10/15 = 0.7* 2/9 (22%) 0/9 (0%)*/** 2/9 (22%)
Incidence = number of mice with tumors/total number of mice (n).
Incidence, T ≥ 500 mm3 = number of mice with tumor volume ≥ 500 mm3/number of tumor-bearing mice.
Multiplicity = number of tumors/total number of mice (n).
Metastasis = number of mice with metastases/number of tumor-bearing mice.
Liver Met = number of mice with liver metastases/number of tumor-bearing mice.
Lung Met = number of mice with lung metastases/number of tumor-bearing mice.
*P < 0.05 compared to placebo.




Figure 3 Pancreas histology and expression of NF-κB and P-ERK. A) H&E. Representative sections of normal adjacent pancreas upon sacrifice
at day 219 [d219]), mPanIN-1 (asterisk) and −2 (black arrowhead) at d271, and pancreatic ductal adenocarcinoma at d258 are shown (200X
magnification). B) NF-κB. Pancreatic tissue sections were immunostained with a NF-κB specific antibody. Representative images of normal
adjacent pancreas at d231, mPanIN-1 (asterisk) and −2 (black arrowhead) at d226, and adenocarcinoma at d239 are shown (200X magnification).
NF-κB is expressed in mPanINs and tumor cells (brown). C) P-ERK. Positive P-ERK staining (brown) was localized to the mPanINs (d226) and tumor
cells (d295) but was absent in normal adjacent pancreas (d226) (200X magnification).
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the study or other gross evidence of drug toxicity was
noted in the treatment groups.
A pilot study was also performed with a related
model suitable for imaging, p53f/f; LSL-KrasG12D;lucl/l;
Pdx-1-Cre mice, in which p53 is deleted and mutant
Kras and luciferase are expressed in the pancreas. The
p53f/f; LSL-KrasG12D;lucl/l; Pdx-1-Cre mice were im-
aged at 10 weeks of age to monitor luciferase expres-
sion and detect bioluminescence (Figure 2A). All mice
expressed luciferase as shown in the three representa-
tive mice, confirming the functional expression of Cre
recombinase in the pancreas by 10 weeks of age; bio-
luminescence was also detected at 6 weeks of age, the
earliest timepoint at which the animals were imaged.
Three weeks after the initial imaging, the same mice
were re-imaged; increased bioluminescence and there-
fore luciferase expression were detected, that should
reflect a corresponding increase in mutant Kras ex-













mPanIN-2, incidence 2/4 = 50%















Figure 4 PanIN analysis. A) The percent normal ducts (N), mPanIN-1 (1), m
group is shown as the mean +/− SEM. B) The percent normal ducts and m
mean +/− SEM. The incidence of mPanIN-2 and mPanIN-3 in pancreata lacof age. Total photon flux significantly increased be-
tween 10 and 13 weeks for the majority of the mice
(Figure 2B). Using this model to test the single agents,
gemcitabine was administered at 8 weeks of age and
significantly increased median survival by approxi-
mately 30 days compared to placebo (155 days vs.
126 days [P = 0.02]), thus confirming gemcitabine’s
beneficial effect (Figure 2C). DMAPT did not signifi-
cantly extend survival (143 days [P = 0.14]).
Effect of treatment on pancreatic tumor incidence, size,
and metastasis
The presence of pancreatic tumors and metastasis in the
LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice was
noted upon necropsy and subsequently confirmed by
histology. Pancreatic adenocarcinomas were detected in
100% of the placebo-treated mice. Tumor incidence was
decreased by treatment with DMAPT (73%) and signifi-
cantly by gemcitabine (43%) as well as the combination
(60%) (Table 1). To confirm that the lack of tumorN 1 2 3 N 1 2 3
Gem DMAPT/Gem
Gemcitabine DMAPT/Gem
3/8 = 38% 1/6 = 17%
3/8 = 38% 1/6 = 17%
N 1 2 3 N 1 2 3
Gem DMAPT/Gem
PanIN-2 (2) and mPanIN-3 (3) for all pancreata within each treatment
PanIN-1, -2 and −3 for pancreata without tumors is presented as the
king tumors is shown in the table below the graph.
*
*






















































Figure 5 NF-κB and Ki67 staining. A) Percent intratumoral NF-κB
staining is shown for the indicated treatment groups (n = 5-6 mice/
group). B) Percent Ki67-positive intratumoral staining is shown (n = 4
mice/group). Results are presented as the mean +/− SEM. * P < 0.05
vs. placebo.
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recombination in the pancreas, PCR was performed
demonstrating successful recombination (Additional file
1: Figure S1). Almost all of the mice without tumors that
died were older (> 200 days old) and/or had other large
primary tumors (lung, lymphoma, liver). Histological
organ examination did not show evidence of drug
toxicity.
The incidence of large pancreatic adenocarcinomas
greater than or equal to 500 mm3 was similar in the pla-
cebo (78%) and DMAPT (73%) groups but was decreased
by treatment with gemcitabine (33%) and significantly with
the combination (11%) (Table 1). Furthermore, pancreatic
tumor volume was significantly decreased by treatment
with the combination DMAPT/gemcitabine compared to
placebo (153 +/− 63.9 mm3 vs. 1329 +/− 338.2 mm3,
respectively) (Figure 1B). Although tumor volume was
also reduced by gemcitabine (601 +/− 343.9 mm3), this
did not reach significance due to the variability in re-
sponse (Figure 1B).
Tumor multiplicity was also significantly reduced by
treatment with gemcitabine or DMAPT/gemcitabine
compared to placebo (0.4 or 0.7 vs. 1.9 tumors/mouse,
respectively) (Table 1). Although the incidence of metas-
tasis was the lowest in the DMAPT/gemcitabine treated
mice, the decrease was not significant; however, the inci-
dence of liver metastasis in mice bearing primary pan-
creatic tumors was significantly reduced from ~50% in
the placebo and gemcitabine groups to 0% in the
DMAPT/gemcitabine treated mice (Table 1). Interest-
ingly, while metastasis occurred to the liver and lung
within the placebo, DMAPT, and gemcitabine groups,
100% of the mice in the DMAPT/gemcitabine group
formed metastases in the lung only (Table 1); statistical
significance cannot be determined due to the low
numbers. Taken together, these results demonstrate
that the combination of DMAPT and gemcitabine is
more effective than the single agents, significantly de-
creasing pancreatic tumor size as well as the incidence
of liver metastasis.
Histological analysis of pancreatic lesions
Premalignant lesions, known as pancreatic intraepithelial
neoplasia (PanINs), arise in the pancreas and are precur-
sors to invasive pancreatic ductal adenocarcinoma [32].
All stages of mouse PanINs (mPanINs) and pancreatic
adenocarcinoma, mirroring those observed in humans,
are represented in the LSL-KrasG12D/+; LSL-Trp53R172H;
Pdx-1-Cre mice (Figure 3A). The percentages of normal
pancreatic ducts and mPanIN-1, -2 and −3 were quanti-
fied for each of the treatment groups; however, no sig-
nificant differences were observed (Figure 4A). Few
mPanINs were present in pancreata bearing large tu-
mors. In addition, pancreata in which no tumors formedwere separately analyzed to determine the extent of pre-
neoplasia (Figure 4B); no significant differences in the %
normal ducts or pancreatic lesions were observed be-
tween the three drug treatment groups. Interestingly,
mostly normal ducts or low grade PanIN-1 lesions were
observed in these pancreata, suggesting that not only
tumor formation but also the development of higher
grade pancreatic lesions is prevented in these animals.
This was also confirmed by the incidence of PanIN-2
and −3 lesions in pancreata lacking tumors (Figure 4B,
table), with the lowest incidence in the DMAPT/Gem
treatment group (17%).
Immunohistochemistry was performed on pancreatic sec-
tions to localize the expression of NF-κB, which was found
to be expressed in cells lining the mPanINs as well as in
pancreatic adenocarcinoma cells (Figure 3B). The over-
expression of NF-κB in non-invasive and invasive pancreatic
neoplasms, but not in normal pancreatic cells, provides evi-
dence that NF-κB is a promising target for chemoprevention
and chemotherapy in this model. Immunohistochemical
staining revealed that phosphorylated mitogen-activated
protein kinase/extracellular signal-regulated kinase 1/2
(P-MAPK/ERK) was strongly expressed in both PanINs
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ERK growth pathway in the LSL-KrasG12D/+; LSL-
Trp53R172H; Pdx-1-Cre pancreatic lesions but not in
histologically normal mouse pancreas (Figure 3C).
Since the animals in this study were not sacrificed at a
set endpoint, optimal evaluation of target inhibition at a
defined timepoint after the last drug dose was not pos-
sible. Nevertheless, intratumoral NF-κB immunohisto-
chemical staining was quantified (Figure 5A), but no
significant difference in NF-κB expression was observed
between placebo and the DMAPT treatment groups.
Quantification of intratumoral Ki67-positive staining
showed a significant decrease in both the gemcitabine and
combination groups (Figure 5B), correlating with the ob-
served anti-tumor effects of these agents. Ki67 staining in
the PanIN lesions did not differ significantly (data not
shown). Pancreatic tissue sections were also stained with a
CD31-specific antibody and Masson’s Trichrome to detect
changes in intratumoral vasculature or stroma, respect-
ively (Figures 6A & C). Intratumoral CD31 expression was
quantified and there was no significant difference between
treatment groups (Figure 6B). Similarly, there was no sig-
nificant difference in the percentage of stroma/collagen as























































Figure 6 CD31 and Masson’s Trichrome staining. A) CD31 immunostain
black arrowheads (400X magnification). B) Percent CD31-positive intratumo
shown as the mean +/− SEM. C) Masson’s Trichrome staining to detect the
collagen staining within each treatment group (n = 5-6 mice/group) is showDMAPT decreases the level of NF-κB-regulated
inflammatory cytokines in mouse plasma
To identify possible indicators or mediators of drug re-
sponse, mouse plasma obtained at the time of sacrifice
was analyzed using the Bio-Plex 200 system that can
simultaneously detect the level of 23 different cyto-
kines and growth factors (interleukin [IL]-1α, IL-1β,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12[p40], IL-
12[p70], IL-13, IL-17, eotaxin, granulocyte-colony stimu-
lating factor [G-CSF], granulocyte-macrophage colony
stimulating factor [GM-CSF], interferon-gamma [IFN-γ],
interleukin-8 homologue KC, monocyte chemotactic
protein-1 [MCP-1, MCAF], macrophage inflammatory
protein-1 alpha [MIP-1α], MIP-1β, RANTES, and tumor
necrosis factor-alpha [TNF-α]). Gemcitabine significantly
increased the plasma levels of IL-1α, IL-1β, and IL-17
compared to placebo (Figures 7A, B & D); DMAPT/
gemcitabine treatment reduced these cytokine levels back
to the placebo levels. DMAPT and DMAPT/gemcitabine
significantly decreased the levels of IL-12p40, MCP-1 and
TNF-α relative to placebo (Figures 7C, E & F). Although
DMAPT and DMAPT/gemcitabine also reduced the levels
of eotaxin and MIP-1β, the decreases were only significant
for the combination (Figures 7G & H). Importantly, these
eight cytokines are proinflammatory cytokines and knownPlacebo DMAPT Gem DMAPT/gem
Placebo DMAPT Gem DMAPT/gem
ing. CD31-positive microvessels (brown) stained as indicated by the
ral staining within each treatment group (n = 4-5 mice/group) is
stromal component (blue) is shown (400X magnification). D) Percent
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Figure 7 (See legend on next page.)
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Figure 7 Plasma levels of NF-κB regulated inflammatory cytokines. Mouse plasma obtained at the time of sacrifice was analyzed using the
Bio-Plex 200 system to determine the concentration of 23 different cytokines and growth factors. The levels of A) IL-1α, B) IL-1β, C) IL-12p40, D)
IL-17, E) MCP-1, F) TNF-α, G) Eotaxin, and H) MIP-1β in placebo (P, n = 8), DMAPT (n = 12), gemcitabine (Gem, n = 10) and DMAPT/gemcitabine
(DM/Gem, n = 9) groups are shown. The means are indicated by the horizontal lines. * P < 0.05 vs. placebo.
Yip-Schneider et al. BMC Cancer 2013, 13:194 Page 11 of 13
http://www.biomedcentral.com/1471-2407/13/194NF-κB target genes. Taken together, these results suggest
that gemcitabine induces the expression of several pro-
inflammatory NF-κB regulated cytokine genes. In contrast,
treatment with DMAPT or the combination reduces the
plasma levels of pro-inflammatory NF-κB-regulated cyto-
kines, demonstrating NF-κB suppression by DMAPT.
Discussion
In the present study, we evaluated the efficacy of the
bioavailable NF-κB inhibitor DMAPT and gemcitabine
using a genetically engineered and clinically relevant
mouse model of pancreatic cancer. Much research
supports a central role for NF-κB in inflammation and
pancreatic tumorigenesis [8,9,11]. We have shown both
in vitro and in vivo that pharmacological suppression of
NF-κB by parthenolide or DMAPT has anti-cancer
activity [15,16,33]. Gemcitabine, the current standard-of-
care therapy for pancreatic cancer, has limited clinical
benefit alone, and recent work has indicated that induc-
tion of NF-κB activity by gemcitabine may be involved
in chemoresistance [9,17-20].
In this study, we report that gemcitabine and DMAPT/
gemcitabine significantly increase median survival and de-
crease the incidence and multiplicity of pancreatic adeno-
carcinomas in LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre
mice. Ki67, a cellular marker of proliferation, staining is
reduced in both gemcitabine and the combination treat-
ment groups, correlating with drug effects on tumor
growth. The DMAPT/gemcitabine combination also sig-
nificantly decreases tumor size as well as the incidence of
metastasis to the liver. Although gemcitabine decreases
tumor size compared to the placebo group, this effect is
not significant. There is also no significant difference be-
tween the combination and gemcitabine alone groups
with respect to tumor size. Furthermore, whereas liver
metastasis in the combination group is significantly re-
duced compared to gemcitabine, the overall incidence of
metastasis is not significantly different between the two
groups due to metastasis occurring in the lung. Thus, it is
not surprising that despite some additional anti-tumor ef-
fects of the combination, no further impact on survival is
observed in our study when compared to gemcitabine
treatment alone. Clinically, such differences, for example
in tumor size, may be beneficial and translate to improved
quality of life for the patient, without prolonging survival.
Many variables (drug bioavailability and dose, treatment
plan, specific mutations present etc.) can influence the ef-
fects of the drugs on tumor response in vivo. Thus, furtheroptimization of the agents, experimental design, or animal
model may be required to observe differential effects on
survival.
No significant difference in premalignant PanIN forma-
tion is apparent between the treatment groups. This is
likely due to the late stage of disease at the time of sacri-
fice and development of large pancreatic adenocarcinomas
especially in the placebo and DMAPT treatment groups
since in many cases, little or no histologically normal or
premalignant pancreas was present. Further analysis spe-
cifically of pancreata lacking primary tumors reveals the
presence of mainly normal ducts or PanIN-1 lesions, with
only a few PanIN-2 and −3 lesions. This suggests that not
only pancreatic tumors but also high grade pancreatic le-
sions are prevented in these animals. It will be of interest
to further characterize the profiles of these “responders”.
We also report that gemcitabine treatment signifi-
cantly increases the levels of the inflammatory cytokines
IL-1α, IL-1β, and IL-17 in mouse plasma. The expres-
sion of these three genes is regulated by NF-κB, so this
effect is consistent with gemcitabine-induced NF-κB ac-
tivation that has been previously reported [34,35]. Treat-
ment with DMAPT/gemcitabine reduces the levels of
these cytokines to that of DMAPT alone. Furthermore,
DMAPT and/or the combination DMAPT/gemcitabine
significantly decrease the levels of the inflammatory cy-
tokines IL-12p40, MCP-1, MIP-1β, eotaxin and TNF-α,
all of which are NF-κB target genes [34]. Thus, the effect
of DMAPT and DMAPT/gemcitabine on the expression
of these cytokines suggests systemic suppression of the
target NF-κB in these treatment groups. Target suppres-
sion was also demonstrated in our recent study with
LSL-KrasG12D; Pdx-1-Cre genetically engineered mice in
which all mice were treated for 3 months and then
sacrificed 3 hours following the last drug treatment; spe-
cifically, combination DMAPT treatment decreased
NF-κB expression in the pancreatic lesions [22]. Thus,
at the 40 mg/kg dose, DMAPT consistently inhibits its
target in models of either established or spontaneous
tumors [15,16].
We previously showed that the percentage of normal
pancreatic ducts was significantly increased by the com-
bination of DMAPT/gemcitabine compared to placebo
in the LSL-KrasG12D; Pdx-1-Cre mouse model; addition-
ally, the percentage of mouse pancreatic intraepithelial
neoplasia-2 (mPanIN-2) lesions was significantly de-
creased by DMAPT/gemcitabine [22]. This delay in PanIN
progression in the LSL-KrasG12D; Pdx-1-Cre mice may in
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gemcitabine to attenuate pancreatic tumorigenesis in the
present study. Similarly, Fendrich et al. recently showed
that treatment with the angiotensin-I-converting enzyme
inhibitor enalapril or aspirin, that targets NF-κB, delays
PanIN progression in LSL-KrasG12D; Pdx-1-Cre mice and
decreases pancreatic cancer development in the LSL-
KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mouse [36]. The
combination of enalapril and asprin was not more effect-
ive than the single agents.
It has been previously reported by Olive et al. that
gemcitabine therapy alone is ineffective in the LSL-
KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mouse model
[37]. In contrast, gemcitabine alone in our study decreases
tumor incidence in LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-
1-Cre mice. In our study, gemcitabine (50 mg/kg, twice
weekly) was administered beginning at 1 month of age
until the time of sacrifice/death. In Olive’s study, mice
bearing tumors ~5-10 mm in diameter were identified
and enrolled for gemcitabine treatment (100 mg/kg,
Q3Dx4 or every third day for 4 cycles). In the latter study,
gemcitabine was given to tumor-bearing mice for a much
shorter time (9 days total); in contrast, for our study,
gemcitabine was administered prior to any palpable tumor
formation (tumors ~5-10 mm in diameter can be detected
by palpation) at 1 month of age until ill health necessitated
sacrifice or death occurred (~6 months of treatment). The
earlier intervention as well as longer length of treatment
may account for the difference in response between these
two studies. Thus, based on these findings, gemcitabine
administered earlier may have some ability to alter the de-
velopment of pancreatic cancer. We speculate this may be
an effect of delaying PanIN progression and/or possibly
improved drug delivery prior to full stromal maturity of
the developing adenocarcinomas. Gemcitabine has rela-
tively low toxicity in humans, and at the comparably lower
doses used in this study, there was no measurable toxicity
in this model. Thus, the use of low dose gemcitabine at
the time of diagnosis or in high risk groups may have
benefit and merits further investigation.
Conclusions
Although survival statistics for many cancers have im-
proved in recent years, pancreatic cancer remains one of
the deadliest diseases with a very poor survival rate due
to the lack of early detection and absence of effective
treatments. Patients at increased risk of pancreatic can-
cer include those with inheritable risk factors, patients
presenting with premalignant pancreatic lesions, and in-
dividuals with multiple epidemiologic risk factors, in-
cluding smoking, diabetes mellitus and obesity [38].
Identifying and monitoring such patients may improve
their clinical outcome by allowing earlier surgical inter-
vention or intervention with agents that can delay orprevent the progression of disease. Once pancreatic can-
cer develops, however, curative treatments are limited.
Thus, novel and effective treatment strategies remain a
critical area of research. In this study, gemcitabine alone
and/or the combination of DMAPT and gemcitabine sig-
nificantly increase median survival as well as decrease
tumor size, the incidence and multiplicity of pancreatic
tumors, and metastasis to the liver in LSL-KrasG12D/+;
LSL-Trp53R172H; Pdx-1-Cre mice. The preclinical evi-
dence presented here supports further evaluation of ei-
ther gemcitabine alone or in combination with DMAPT
or related agents as intervention to delay the progression
of pancreatic cancer.Additional file
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